NZ607615A - Antibodies directed against il-17 - Google Patents
Antibodies directed against il-17Info
- Publication number
- NZ607615A NZ607615A NZ60761511A NZ60761511A NZ607615A NZ 607615 A NZ607615 A NZ 607615A NZ 60761511 A NZ60761511 A NZ 60761511A NZ 60761511 A NZ60761511 A NZ 60761511A NZ 607615 A NZ607615 A NZ 607615A
- Authority
- NZ
- New Zealand
- Prior art keywords
- directed against
- antibodies directed
- seq
- chain polypeptide
- isolated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37097810P | 2010-08-05 | 2010-08-05 | |
| PCT/US2011/046201 WO2012018767A2 (en) | 2010-08-05 | 2011-08-02 | Antibodies directed against il-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ607615A true NZ607615A (en) | 2015-03-27 |
Family
ID=45560018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ60761511A NZ607615A (en) | 2010-08-05 | 2011-08-02 | Antibodies directed against il-17 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9328166B2 (enExample) |
| EP (1) | EP2601217B1 (enExample) |
| JP (1) | JP2013537414A (enExample) |
| CN (1) | CN103154026B (enExample) |
| AU (1) | AU2011285922B2 (enExample) |
| BR (1) | BR112013002831A2 (enExample) |
| ES (1) | ES2633145T3 (enExample) |
| NZ (1) | NZ607615A (enExample) |
| RU (1) | RU2595385C2 (enExample) |
| WO (1) | WO2012018767A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2577228C2 (ru) * | 2014-03-14 | 2016-03-10 | Закрытое Акционерное Общество "Биокад" | Анти-il-17-антитела, способ их получения и способ применения |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| CN105315371B (zh) | 2015-03-05 | 2018-05-29 | 北京百特美博生物科技有限公司 | 抗人il-17单克隆抗体 |
| CN105399827B (zh) * | 2015-11-02 | 2018-11-09 | 东南大学 | Wasabi蛋白纳米抗体及其编码序列与应用 |
| CN107236041B (zh) * | 2016-03-29 | 2020-07-24 | 舒泰神（北京）生物制药股份有限公司 | Il-17抗体 |
| CN107488227A (zh) * | 2016-06-12 | 2017-12-19 | 三生国健药业（上海）股份有限公司 | 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用 |
| US11619832B2 (en) | 2018-03-08 | 2023-04-04 | Coopervision International Limited | Identification of contact lens wearers predisposed to contact lens discomfort |
| JP7525499B2 (ja) | 2019-01-31 | 2024-07-30 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法 |
| EP3689907A1 (en) | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
| JP7686571B2 (ja) | 2019-05-08 | 2025-06-02 | ヤンセン バイオテツク，インコーポレーテツド | Ｔ細胞媒介性免疫を調節するための材料及び方法 |
| US12076413B2 (en) * | 2020-10-28 | 2024-09-03 | Janssen Biotech, Inc. | Compositions and methods for modulating delta gamma chain mediated immunity |
| CN112646030B (zh) * | 2021-01-11 | 2021-11-30 | 内蒙古创润生物科技有限公司 | 一种包含间充质干细胞外泌体的药物组合物在治疗疾病中的应用 |
| CN121731462A (zh) * | 2024-09-27 | 2026-03-27 | 百奥泰生物制药股份有限公司 | 抗il-17抗体制剂及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050058649A1 (en) * | 2002-12-02 | 2005-03-17 | Landes Gregory M. | Antibodies directed to phospholipase A2 and uses thereof |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| US8029783B2 (en) * | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
| PL1963368T6 (pl) | 2005-12-13 | 2021-02-08 | Eli Lilly And Company | Przeciwciała anty-IL-17 |
| CA2637166A1 (en) | 2006-01-31 | 2007-10-18 | Novartis Ag | Il-17 antagonistic antibodies for treating cancer |
| GB0612928D0 (en) * | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| NZ574804A (en) * | 2006-08-11 | 2012-02-24 | Schering Corp | Antibodies to il-17a |
| CA2737636A1 (en) * | 2008-09-29 | 2010-04-01 | Roche Glycart Ag | Antibodies against human il17 and uses thereof |
| WO2011056864A1 (en) | 2009-11-05 | 2011-05-12 | Anaptysbio, Inc. | Methods of generating improved antigen-binding agents using chain shuffling and optionally somatic hypermutation |
-
2011
- 2011-08-02 WO PCT/US2011/046201 patent/WO2012018767A2/en not_active Ceased
- 2011-08-02 EP EP11815158.8A patent/EP2601217B1/en active Active
- 2011-08-02 BR BR112013002831A patent/BR112013002831A2/pt not_active Application Discontinuation
- 2011-08-02 ES ES11815158.8T patent/ES2633145T3/es active Active
- 2011-08-02 CN CN201180048098.2A patent/CN103154026B/zh active Active
- 2011-08-02 AU AU2011285922A patent/AU2011285922B2/en active Active
- 2011-08-02 JP JP2013523260A patent/JP2013537414A/ja active Pending
- 2011-08-02 RU RU2013109397/10A patent/RU2595385C2/ru active
- 2011-08-02 NZ NZ60761511A patent/NZ607615A/en unknown
- 2011-08-02 US US13/814,262 patent/US9328166B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2013109397A (ru) | 2014-09-10 |
| EP2601217B1 (en) | 2017-06-14 |
| US9328166B2 (en) | 2016-05-03 |
| EP2601217A4 (en) | 2014-03-05 |
| AU2011285922A1 (en) | 2013-03-21 |
| US20130202591A1 (en) | 2013-08-08 |
| RU2595385C2 (ru) | 2016-08-27 |
| CN103154026B (zh) | 2016-07-06 |
| WO2012018767A2 (en) | 2012-02-09 |
| JP2013537414A (ja) | 2013-10-03 |
| WO2012018767A3 (en) | 2012-05-10 |
| BR112013002831A2 (pt) | 2016-11-01 |
| ES2633145T3 (es) | 2017-09-19 |
| EP2601217A2 (en) | 2013-06-12 |
| CN103154026A (zh) | 2013-06-12 |
| AU2011285922B2 (en) | 2016-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA111818C2 (uk) | Антитіло проти csf-1r | |
| NZ703653A (en) | Anti-fap antibodies and methods of use | |
| NZ596295A (en) | Anti-5T4 antibodies and uses thereof | |
| NZ616382A (en) | Antibodies specific to cadherin-17 | |
| NZ584838A (en) | Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| NZ610091A (en) | Antibodies | |
| EA035160B9 (ru) | Антитела к st2 и их применение | |
| NZ702494A (en) | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| NZ724296A (en) | Antibodies for treatment of cancer expressing claudin 6 | |
| NZ600022A (en) | Anti CD37 antibodies | |
| NZ712765A (en) | Antibodies that bind csf1r | |
| MX2018015933A (es) | Epitopes de celulas t reguladoras, composiciones y usos para los mismos. | |
| WO2012018767A3 (en) | Antibodies directed against il-17 | |
| NZ607969A (en) | Cd33 binding agents | |
| NZ588457A (en) | Humanized anti-factor d antibodies and uses thereof | |
| ES2685823T3 (es) | Anticuerpos antagonistas anti-CD40 | |
| IN2012DN05237A (enExample) | ||
| NZ601271A (en) | Cd127 binding proteins | |
| NZ599737A (en) | Il-17a antagonists | |
| CL2016000344A1 (es) | Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
| NZ592214A (en) | Improved Interleukin-6 receptor antibody molecule | |
| NZ597692A (en) | Anti-IGF antibodies | |
| NZ590890A (en) | Neutralizing anti-influenza a virus antibodies and uses thereof | |
| NZ700473A (en) | Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2016 BY CPA GLOBAL Effective date: 20151012 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2017 BY CPA GLOBAL Effective date: 20160617 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2018 BY CPA GLOBAL Effective date: 20170615 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2019 BY CPA GLOBAL Effective date: 20180622 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2020 BY CPA GLOBAL Effective date: 20190620 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2021 BY CPA GLOBAL Effective date: 20200618 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2022 BY CPA GLOBAL Effective date: 20210617 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2023 BY CPA GLOBAL Effective date: 20220616 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2024 BY CPA GLOBAL Effective date: 20230615 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240620 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20250619 |